Key Points
- CEO Jason Coloma sold 34,501 Maze Therapeutics shares at an average price of $27.02, generating approximately $932,217. The Rule 10b5-1 transaction reduced his direct holdings by 68.92% to 15,558 shares.
- Maze shares opened at $26.43, with a market capitalization of about $1.47 billion and a 52-week range of $21.95 to $53.65. The company reported a quarterly loss of $0.76 per share, in line with analyst expectations.
- Analyst sentiment remains broadly positive, with a consensus “Buy” rating and a $63.40 price target, despite some sell ratings. Several institutional investors, including Frazier Life Sciences Management and Braidwell, increased or initiated positions during the second quarter.
Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) CMO Harold Bernstein sold 16,141 shares of Maze Therapeutics stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $26.93, for a total transaction of $434,677.13. Following the sale, the chief marketing officer owned 16,141 shares in the company, valued at $434,677.13. This represents a 50.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Harold Bernstein also recently made the following trade(s):
- On Friday, September 4th, Harold Bernstein sold 9,705 shares of Maze Therapeutics stock. The shares were sold at an average price of $26.22, for a total value of $254,465.10.
- On Thursday, September 3rd, Harold Bernstein sold 5,189 shares of Maze Therapeutics stock. The shares were sold at an average price of $26.01, for a total transaction of $134,965.89.
- On Wednesday, September 2nd, Harold Bernstein sold 5,106 shares of Maze Therapeutics stock. The shares were sold at an average price of $26.47, for a total transaction of $135,155.82.
- On Tuesday, September 1st, Harold Bernstein sold 16,141 shares of Maze Therapeutics stock. The stock was sold at an average price of $26.36, for a total value of $425,476.76.
- On Thursday, August 13th, Harold Bernstein sold 16,142 shares of Maze Therapeutics stock. The stock was sold at an average price of $27.61, for a total transaction of $445,680.62.
Maze Therapeutics Price Performance
Shares of MAZE opened at $26.43 on Friday. The stock has a market cap of $1.47 billion, a P/E ratio of -10.49 and a beta of 2.16. The stock's 50-day moving average price is $26.97 and its two-hundred day moving average price is $28.22. The company has a current ratio of 18.31, a quick ratio of 18.31 and a debt-to-equity ratio of 0.09. Maze Therapeutics, Inc. has a 1 year low of $21.95 and a 1 year high of $53.65.
Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.76). On average, equities analysts predict that Maze Therapeutics, Inc. will post -2.72 earnings per share for the current year.
Analyst Ratings Changes
MAZE has been the subject of a number of recent analyst reports. BTIG Research reiterated a "buy" rating and issued a $46.00 price target on shares of Maze Therapeutics in a research note on Tuesday, September 22nd. HC Wainwright reaffirmed a "buy" rating and issued a $110.00 target price on shares of Maze Therapeutics in a report on Thursday, September 24th. Wedbush reiterated an "outperform" rating and set a $48.00 price target on shares of Maze Therapeutics in a report on Wednesday, September 23rd. TD Cowen raised Maze Therapeutics to a "strong-buy" rating in a research report on Monday, August 24th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Maze Therapeutics in a research note on Monday, September 21st. Three analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $63.40.
Read Our Latest Stock Analysis on MAZE
Institutional Trading of Maze Therapeutics
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in Maze Therapeutics in the 2nd quarter valued at about $48,000. Royal Bank of Canada boosted its holdings in shares of Maze Therapeutics by 214.1% during the first quarter. Royal Bank of Canada now owns 2,029 shares of the company's stock worth $61,000 after acquiring an additional 1,383 shares during the period. Quantbot Technologies LP acquired a new position in shares of Maze Therapeutics in the second quarter valued at approximately $80,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Maze Therapeutics in the fourth quarter valued at approximately $145,000. Finally, Persistent Asset Partners Ltd bought a new position in shares of Maze Therapeutics during the second quarter worth approximately $200,000.
Maze Therapeutics Company Profile
(
Get Free Report)
Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetic diseases. The company uses human genetics and its Maze Compass platform to identify disease-causing biological mechanisms and design small-molecule therapies intended to address the underlying drivers of disease.
Maze's pipeline includes MZE001, an investigational oral therapy designed to inhibit glycogen synthase as a potential treatment for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
